Milestone Pharmaceuticals MIST 深 滬
等待開盤 12-12 09:30:00 美东时间
2.95
+0.280
+10.49%
華盛通- 最 高2.965
- 今 開2.63
- 成交量 752.93万股
- 最 低 2.6037
- 昨 收 2.67
- 總市值 2.51亿
- 52周最高 2.965
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 0.6254
- 委 比 -14.29%
- 總股本 8499.43万
- 歷史最高 27.95
- 量 比 1.97
- 振 幅 13.53%
- 歷史最低 0.6254
- 每 手 1
- 風險率 0.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals Inc. granted 30,000 stock options to two new employees under its 2021 Inducement Plan, with a grant date of December 1, 2025, and an exercise price of $2.69 per share. The options vest over four years, with 25% vesting after one year and the remainder vesting monthly. The awards are contingent on continued employment through each vesting date and comply with Nasdaq Listing Rule 5635(c)(4). Milestone is a biopharmaceutica...
12-02 22:21
Milestone Pharmaceuticals Prepares for CARDAMYST Launch Amid Financial Growth
Milestone Pharmaceuticals ( ($MIST) ) just unveiled an update. Milestone Pharma...
11-13 03:02
Milestone Pharmaceuticals Q3 EPS $(0.12) Beats $(0.16) Estimate
Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 26.83 percent. This is a 14.29 percent increase over losses of $(0.14) per
11-12 20:03
Milestone Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Milestone Pharmaceuticals reported a cash balance of $82.6 million as of September 30, 2025, and completed an equity offering raising approximately $48.7 million, enhancing its readiness for the potential launch of CARDAMYST™ (etripamil) nasal spray following the December 13, 2025 FDA PDUFA date. The company strengthened commercial capabilities and anticipates a quick market entry upon approval. Recent clinical data demonstrated etripamil's consi...
11-12 12:01
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Milestone Pharmaceuticals Inc. granted 65,000 stock options to a new employee under its 2021 Inducement Plan. The options, with a grant date of November 3, 2025, have an exercise price of $1.85 per share, matching the closing price on the grant date. The shares will vest over four years, with 25% vesting after the first year and the remainder vesting in 36 monthly installments. The awards are subject to continuous service and the terms of the Pla...
11-04 21:05
Milestone Pharma Says New Data Analyses Of Investigational Product For PSVT, Etripamil Nasal Spray, Consistently Showed Efficacy And Favorable Safety Profile Across Multiple Studies Comprising Global Development Program
Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that new data analyses
11-03 21:11
MISTRAS Group to Participate in Baird’s 55th Annual Global Industrial Conference on November 12, 2025
MISTRAS Group's CEO Natalia Shuman and CFO Edward Prajzner will present at Baird’s 55th Annual Global Industrial Conference on November 12, 2025, at 4:40 PM CT in Chicago. The presentation will be live webcast, and registration is available via the provided link. MISTRAS, a leader in industrial asset integrity solutions, serves key industries including oil & gas, aerospace, and power utilities, offering advanced testing and monitoring services. V...
10-16 12:00
MISTRAS Group Partnering with Villari to Offer Wireless Crack-Detection Sensors for Critical Steel Assets
MISTRAS Group collaborates with Villari to offer a wireless crack-detection system for steel structures, enhancing continuous monitoring and proactive maintenance. Villari's unique technology detects fatigue cracks earlier than traditional methods, combining with MISTRAS' expertise to improve safety, reliability, and efficiency. The solution benefits industries like wind energy, oil & gas, bridges, ports, and steel manufacturing by extending asse...
10-14 12:00
Milestone Scientific Highlights Operational Progress and Growth Initiatives Under New Leadership
Milestone Scientific Inc. CEO Eric Hines has implemented strategic initiatives to accelerate growth, strengthen market position, and improve efficiency across its dental and medical segments. Key actions include expanding sales programs, enhancing digital marketing, and securing international registrations. The company has reduced operating expenses by 20% in Q3, driven by increased interest in CompuFlo® and STA®. These efforts aim to boost both ...
10-14 11:50
Milestone® Pharmaceuticals to Present Data on Etripamil at the American Heart Association Scientific Sessions 2025
Milestone Pharmaceuticals will present a poster at the American Heart Association Scientific Sessions 2025 in New Orleans on November 10, 2025. The presentation, led by James Ip, M.D., will discuss the efficacy, safety, and tolerability of self-administered etripamil for treating paroxysmal supraventricular tachycardia (PSVT). Milestone recently submitted an NDA for etripamil to the FDA.
10-09 12:00
